JAC Advance Access originally published online on December 17, 2007
Journal of Antimicrobial Chemotherapy 2008 61(2):362-364; doi:10.1093/jac/dkm496
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Original research |
Unexpected antimicrobial effect of statins
1 Department of Microbiology and Infectious Diseases, Royal Sussex County Hospital, Eastern Road, Brighton BN2 5BE, UK 2 Brighton and Sussex Medical School, University of Sussex, Falmer BN1 9PX, UK
Received 25 October 2007; returned 16 November 2007; revised 27 November 2007; accepted 27 November 2007
* Corresponding author. Tel: +44-1273-877577; Fax: +44-1273-877575; E-mail: j.cohen{at}bsms.ac.uk
Objectives: Epidemiological studies of statins have suggested a link between statin therapy and a decreased risk of sepsis. It has been proposed that the mechanism underlying this apparent protective effect of statins relates to their known immunomodulatory and anti-inflammatory effects. The aim of this study was to explore the antimicrobial effect of statins.
Methods: Simvastatin (Merck) and fluvastatin (Novartis) were both tested against six of each of methicillin-susceptible and -resistant Staphylococcus aureus (MSSA + MRSA), and vancomycin-sensitive and -resistant enterococci (VSE + VRE) using a microtitre dilution method. The test was repeated five times for both statins against all 24 isolates. Vancomycin, linezolid and propranolol were used as controls, as appropriate.
Results and discussion: Simvastatin showed a significant antimicrobial effect against MSSA (mean MIC 29.2 mg/L) and to a lesser extent against MRSA (mean MIC 74.9 mg/L). Fluvastatin had a significantly less marked antimicrobial effect. Propranolol showed no antimicrobial effect. Simvastatin has a considerable antimicrobial effect in vitro and further testing of it is warranted.
Keywords: antimicrobial activity , susceptibility testing , Staphylococcus aureus
![]()
CiteULike
Connotea
Del.icio.us What's this?
This article has been cited by other articles:
![]() |
V. Chopra and S. A. Flanders Does Statin Use Improve Pneumonia Outcomes? Chest, November 1, 2009; 136(5): 1381 - 1388. [Abstract] [Full Text] [PDF] |
||||
![]() |
N. Daneman, D. Thiruchelvam, and D. A. Redelmeier Statin Use and the Risk of Surgical Site Infections in Elderly Patients Undergoing Elective Surgery Arch Surg, October 1, 2009; 144(10): 938 - 945. [Abstract] [Full Text] [PDF] |
||||
![]() |
H.-C. Chiu, J. Yang, S. Soni, S. K. Kulp, J. S. Gunn, L. S. Schlesinger, and C.-S. Chen Pharmacological Exploitation of an Off-Target Antibacterial Effect of the Cyclooxygenase-2 Inhibitor Celecoxib against Francisella tularensis Antimicrob. Agents Chemother., July 1, 2009; 53(7): 2998 - 3002. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. R. Nalin Comment on: Unexpected antimicrobial effect of statins J. Antimicrob. Chemother., June 1, 2008; 61(6): 1400 - 1400. [Full Text] [PDF] |
||||



